Skip to content

Study · Non-randomized trial · n = 8 · 2004

6 results

Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes.

Dupré J, Behme MT, McDonald TJ

The Journal of clinical endocrinology and metabolism1 Jul 2004Cited by 90 (Europe PMC)

PMID15240633 (opens in a new tab)DOI10.1210/jc.2003-032001 (opens in a new tab)PepBankPUB-15240633
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In volunteers with type 1 diabetes, exendin‑4 reduced the mean postmeal glucose excursion by 90% with an unstated comparator.

    In plain wordsIn volunteers with type 1 diabetes, exendin‑4 reduced postmeal glucose excursions with an unstated comparator.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostmeal glucose excursion
    Study

    n = 8

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Measurements

    Glucose excursion reduction
    90%
    after breakfast

    Source sentences

    Summary
    The mean plasma glucose excursion was reduced by 90%, falling into the normal range, after breakfast, whereas plasma pancreatic polypeptide, glucagon, and acetaminophen levels were reduced, and insulin levels were not affected.
    1 context sentence
    Summary · context
    Subsequently, exendin-4 was administered 15 min before breakfast, with usual insulin, to eight of the volunteers.
  2. 02HumanNon-randomized trialEfficacy outcome

    In volunteers with type 1 diabetes, exendin‑4 reduced plasma pancreatic polypeptide levels with an unstated comparator.

    In plain wordsIn volunteers with type 1 diabetes, exendin‑4 lowered pancreatic polypeptide levels with an unstated comparator.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePancreatic polypeptide levels
    Study

    n = 8

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The mean plasma glucose excursion was reduced by 90%, falling into the normal range, after breakfast, whereas plasma pancreatic polypeptide, glucagon, and acetaminophen levels were reduced, and insulin levels were not affected.
    1 context sentence
    Summary · context
    Subsequently, exendin-4 was administered 15 min before breakfast, with usual insulin, to eight of the volunteers.
  3. 03HumanNon-randomized trialEfficacy outcome

    In volunteers with type 1 diabetes, exendin‑4 reduced plasma glucagon levels with an unstated comparator.

    In plain wordsIn volunteers with type 1 diabetes, exendin‑4 lowered glucagon levels with an unstated comparator.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGlucagon levels
    Study

    n = 8

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The mean plasma glucose excursion was reduced by 90%, falling into the normal range, after breakfast, whereas plasma pancreatic polypeptide, glucagon, and acetaminophen levels were reduced, and insulin levels were not affected.
    1 context sentence
    Summary · context
    Subsequently, exendin-4 was administered 15 min before breakfast, with usual insulin, to eight of the volunteers.
  4. 04HumanNon-randomized trialEfficacy outcome

    In volunteers with type 1 diabetes, exendin‑4 reduced plasma acetaminophen levels with an unstated comparator, consistent with delayed gastric emptying.

    In plain wordsIn volunteers with type 1 diabetes, exendin‑4 lowered the gastric emptying marker acetaminophen with an unstated comparator.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAcetaminophen levels
    Study

    n = 8

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The mean plasma glucose excursion was reduced by 90%, falling into the normal range, after breakfast, whereas plasma pancreatic polypeptide, glucagon, and acetaminophen levels were reduced, and insulin levels were not affected.
    2 context sentences
    Summary · context
    Acetaminophen was ingested with the meal as an indicator of gastric emptying.
    Summary · context
    Subsequently, exendin-4 was administered 15 min before breakfast, with usual insulin, to eight of the volunteers.
  5. 05HumanNon-randomized trialEfficacy outcome

    In volunteers with type 1 diabetes, exendin‑4 did not affect insulin levels with an unstated comparator.

    In plain wordsIn volunteers with type 1 diabetes, exendin‑4 did not change insulin levels with an unstated comparator.

    Peptide
    Exenatide (exendin-4)
    Outcome
    No significant changeInsulin levels
    Study

    n = 8

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    The mean plasma glucose excursion was reduced by 90%, falling into the normal range, after breakfast, whereas plasma pancreatic polypeptide, glucagon, and acetaminophen levels were reduced, and insulin levels were not affected.
    1 context sentence
    Summary · context
    Subsequently, exendin-4 was administered 15 min before breakfast, with usual insulin, to eight of the volunteers.
  6. 06HumanNon-randomized trialSafety outcome

    In volunteers with type 1 diabetes, investigators established a side effect-free dose of exendin‑4.

    In plain wordsIn volunteers with type 1 diabetes, investigators identified an exendin‑4 dose without side effects.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableSide effect-free dose
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    We established a side effect-free dose and an appropriate antecibal time for sc administration of exendin-4.
    1 context sentence
    Summary · context
    We tested a range of doses of exendin-4 on postcibal glycemic excursions in nine volunteers with type 1 diabetes, all with negligible endogenous insulin secretion, in paired comparisons with vehicle in at least six volunteers with each of six doses.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.